We identify and develop growth opportunities with our partners
Our focus in business development is to identify new opportunities for our existing products, and to add new technologies and services to our portfolio to further evolve our business. To accomplish that we are continuously looking for business partners that have an ingenious idea and interest in collaborating with us – for entering new channels, developing new techniques or expanding into new markets.
B·R·A·H·M·S Biomarkers focuses on in vitro diagnostics (IVD) in medically relevant areas such as:
- Sepsis and infectious diseases
- Cardiovascular diseases
- Prenatal screening with Down syndrome and pre-eclampsia
- Endocrinology and metabolic disorders
Our established technologies enable safe and reliable measurement of biomarkers
Once a biomarker has been identified valuable for a medical need we make it measurable with diverse technologies and our own laboratory platform system KRYPTOR®. All KRYPTOR systems use the unique TRACE® technology (Time-Resolved Amplified Cryptate Emission) which is known for its accuracy.
- B·R·A·H·M·S KRYPTOR laboratory systems
- Point-of-care technology
Your idea, invention, product, or service
You have identified and validated a new biomarker and demonstrated its clinical utility? Your work has the potential to improve the diagnosis of patients with severe acute or chronic disease, or to guide targeted therapies in a theranostics / companion diagnostics approach? Diagnostic biomarkers that can be employed for selecting targeted therapies are of specific interest for us.
Or have you developed a concept for a new technique that helps measuring a biomarker reliably in the central laboratory, or at the point-of-care? We are interested to learn more – please contact us with an initial, brief, non-confidential description of your concepts or products. We will get back to you in order to jointly explore a collaboration or business partnership.
B·R·A·H·M·S biomarkers and technologies available for partnering
B·R·A·H·M·S is a pioneer in developing new biomarkers and recognized expert in validating biomarkers for clinical practice to address the needs of patients and care-takers.
In our own research program, B·R·A·H·M·S has developed a number of biomarkers whose suitability for diagnosis, prognosis and therapy monitoring has been confirmed in extensive clinical trials. These biomarkers – mainly from the areas of sepsis, cardiovascular disease and oncology – have the potential to support effective, patient-specific treatment choices (companion diagnostics, theranostics).
Our capabilities in
- in-vitro diagnostics range from discovery to CE certification/FDA approval, and include:
- Biomarker discovery and validation
- Assay development
- Clinical development
- Regulatory affairs
- Production Quality Control
- Marketing & Sales
- Successful track record of proprietary IVD discovery, development and external cooperations
- Reliable partner in OEM manufacturing
|Tel:||+49 3302 883 973|
|Fax:||+49 3302 883 649|